Follicular Lymphoma

Follicular lymphoma is one of the most common kinds of non-Hodgkin lymphoma. Its progression rate varies widely, though it tends to spread slowly and has few symptoms. Patients with follicular lymphoma usually survive ten years or longer.
What is Follicular Lymphoma?

Follicular lymphoma is a cancer of the B-cells that accounts for around one third of all cases of lymphoma. The cancer is a form of non-Hodgkin lymphoma that usually affects adults, with an average age-at-diagnosis of 60. Follicular lymphoma is more common among women than among men.

Read More

Overview

Feature Articles

Latest Follicular Lymphoma News and Research

Study shows potential new approach to treating two common subtypes of lymphoma

Study shows potential new approach to treating two common subtypes of lymphoma

8 Jan 2020
Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

9 Dec 2019
Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

8 Dec 2019
Cancer patients share survivorship story, celebrate strength and self-care

Cancer patients share survivorship story, celebrate strength and self-care

16 Jun 2019
HCA Healthcare UK introduces ground-breaking new blood cancer treatment

HCA Healthcare UK introduces ground-breaking new blood cancer treatment

3 Apr 2019
T-cells play key role in how the body fights follicular lymphoma

T-cells play key role in how the body fights follicular lymphoma

20 Feb 2019
CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

3 Dec 2018
Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

1 Nov 2018
Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

10 Oct 2018
NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

8 Oct 2018
Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

28 Sep 2018
FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

24 Sep 2018
Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

6 Sep 2018
Celgene to share new and updated data around novel hematological therapies

Celgene to share new and updated data around novel hematological therapies

22 May 2018
New compounds targeting epigenetics show promise in lymphoma patients

New compounds targeting epigenetics show promise in lymphoma patients

5 Mar 2018
Study reveals HCT as effective treatment for NHL patients regardless of age

Study reveals HCT as effective treatment for NHL patients regardless of age

21 Feb 2018
CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

CAR T cell therapy shows long-lasting remissions in non-Hodgkin's lymphoma patients

11 Dec 2017
VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patients

VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patients

25 Oct 2017
Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

20 Oct 2017
FDA grants accelerated approval to new drug for treating relapsed follicular lymphoma

FDA grants accelerated approval to new drug for treating relapsed follicular lymphoma

14 Sep 2017

Newsletters you may be interested in

See all Newsletters »